Nektar Therapeutics
0UNL.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.18B
Close$
$-28.04
174% downside
Current Fair Value
174% downsideOvervalued by 174% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.18 Billion |
|---|---|
| Enterprise Value | $1.22 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-9.73 |
| Beta | 1.16 |
| Outstanding Shares | 33,054,865 |
Return
| Return on Equity | -17.40% |
|---|---|
| Return on Assets | -14.35% |
| Return on Invested Capital | -13.73% |
Valuation & Multiples
| P/E Ratio | -6.14 |
|---|---|
| PEG | 263.21 |
| Price to Sales | 37.87 |
| Price to Book Ratio | 1.4 |
| Enterprise Value to Revenue | 22.36 |
| Enterprise Value to EBIT | -8.68 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-1.97
Average shareholder expectationRevenue Estimate
$10.43 M
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-2.07
Average shareholder expectationRevenue Estimate
$10.27 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Nektar Therapeutics
63 employees
CEO: Howard Robin Nektar Therapeutics is a biopharmaceutical firm dedicated to identifying and advancing medical treatments for critical health conditions lacking effective therapies, serving markets across the United States and globally. Its diverse pipe...